Quest Diagnostics (DGX) has emerged as a high performing healthcare stock outpacing its medical peers. Aiding this growth is the industry-first collaboration with Epic promising improved laboratory testing experience, increased holdings by Pacer Advisors Inc, and the acquisition of clinical testing assets from Fresenius Medical Care. The company also reported strong Q3 2025 financial results signalling steady share price performance and a raised outlook. Quest Diagnostics has further increased its service portfolio by offering FDA-cleared Fujirebio blood test for Alzheimer’s disease, testing for Oropouche virus, and launching an advanced Pharmacogenomics (PGx) offering. Introducing advanced lab services through Corewell joint venture and a strategic collaboration with Guardant Health promises wider screening test access in the United States. The company, undeterred by perceived tariff and Medicare Act risks, raises its full-year guidance while consistently beating earnings estimates. Future prospects look promising, especially with Google Cloud collaboration aiming to personalize customer experiences using Generative AI. The introduction of the MCaST blood test based on MD Anderson Technology marks a progressive stride in cancer diagnostics, as does Quest's Shield partnership transformation in preventive health innovation.
Quest Diagnostics DGX News Analytics from Thu, 30 Jan 2025 08:00:00 GMT to Fri, 26 Dec 2025 12:03:58 GMT -
Rating 8
- Innovation 4
- Information 7
- Rumor 3
